ERBB2 and triple-negative breast carcinoma: Nodal positivity was identified in 22 patients (29.0%) with hormone receptor+/human epidermal growth factor receptor 2− tumours, 12 patients (13.8%) with hormone receptor+/human epidermal growth factor receptor 2+ tumours, 3 patients (5.6%) with hormone receptor−/human epidermal growth factor receptor 2+ tumours, and 10 patients (6.5%) with triple-negative breast cancer.